Bausch Health Companies Inc. (BHC) 2024 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Greetings and welcome to the Bausch Health First Quarter 2024 earnings call. At this time, all participants are on a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. I would now like to turn the conference over to your host, Garen Sarafian, Investor Relations at Belden. You may begin.

    您好,歡迎參加 Bausch Health 2024 年第一季財報電話會議。此時所有與會者皆為僅收聽模式。正式簡報結束後將進行問答環節。請注意,本次會議將被錄音。現在我想把會議交給本次主持人 Belden 投資人關係部的 Garen Sarafian。您可以開始了。

  • Garen Sarafian - Investor Relations

    Garen Sarafian - Investor Relations

  • Good morning, and welcome to Bausch Health First Quarter 2024 earnings conference call. Participating in today's call are Thomas Apio, Chief Executive Officer of Bausch Health, and John veracity, Interim Chief Financial Officer.

    各位早安,歡迎參加 Bausch Health 2024 年第一季財報電話會議。今天參與會議的有 Bausch Health 執行長 Thomas Apio,以及代理財務長 John veracity。

  • Before we begin, I'd like to remind you that our presentation today contains forward-looking information, and we ask you to take a moment to read the forward-looking statements disclaimer at the beginning of the slides that accompany this presentation. As it contains important information, our actual results may vary materially from those expressed or implied in our forward-looking statements, and you should not place undue reliance on any forward looking statements, please refer to our SEC filings and filings with the Canadian securities administrators for a list of some of the risk factors that could cause our actual results to differ materially from our expectations. We use non-GAAP financial measures to help investors understand our ongoing business performance. Non-gaap financial measures may not be comparable to similarly titled measures used by other companies and should be considered along with, but not as an alternative to measures calculated in accordance with GAAP. So I find reconciliations to our non-GAAP measures in the appendix of the slides that accompany this presentation, which are available on Bausch Health Investor Relations website.

    在開始之前,我想提醒各位,我們今天的簡報包含前瞻性資訊,並請您花點時間閱讀本簡報投影片開頭的前瞻性聲明免責聲明。其中包含重要資訊;我們的實際結果可能與前瞻性聲明中明示或暗示的內容有重大差異,您不應過度依賴任何前瞻性聲明。請參閱我們向 SEC 提交的文件以及向加拿大證券主管機關提交的文件,其中列示部分可能導致實際結果與我們預期有重大差異的風險因素。我們使用非 GAAP 財務衡量指標,以協助投資人了解我們持續的營運表現。非 GAAP 財務衡量指標可能無法與其他公司使用的同名指標相互比較,且應與依 GAAP 計算的衡量指標一併考量,但不應作為其替代。因此,您可在隨附本簡報之投影片附錄中找到我們非 GAAP 指標的調節表;投影片可於 Bausch Health 投資人關係網站取得。

  • Finally, the financial guidance in this presentation is effective as of today only. We do not undertake any obligation to update guidance. Our discussion today, Thursday, May second, will focus on Bausch Health, excluding Bausch & Lomb. However, we will briefly comment on Bausch & Lomb's results announced yesterday. We will refer to year-over-year comparisons with the same period last year, unless otherwise noted.

    最後,本簡報中的財務指引僅於今日有效。我們不承擔更新指引的任何義務。我們今天(5 月 2 日,星期四)的討論將聚焦於 Bausch Health(不含 Bausch & Lomb)。不過,我們將簡要評論 Bausch & Lomb 昨日公布的業績。除非另有說明,我們提及的年對年比較皆以去年同期為基準。

  • With that, it is my pleasure to turn the call over to our CEO, Thomas Avio.

    接下來,我很高興把電話會議交給我們的執行長 Thomas Avio。

  • Thomas Appio - Chief Executive Officer

    Thomas Appio - Chief Executive Officer

  • Tom, thank you, and welcome to those of you joining the call this morning, we started 2024 on strong footing, building on the momentum we have established last year, while maintaining our focus on operational excellence and our Patient Centered mentality. We delivered another quarter of growth, making our fourth consecutive quarter of year over year growth in both revenue and adjusted EBITDA for the first quarter of 2024. Revenues for Bausch Health, excluding B&L, were $1.05 billion, up $41 million or 4% on a reported basis and 5% on an organic basis. All segments delivered revenue growth on both a reported and organic basis when compared to the first quarter of 2023, led by Solta with 23% organic growth. Adjusted EBITDA for Bausch Health, excluding B&L, was $504 million, an increase of approximately 9% compared to the prior year.

    Tom,謝謝你;也歡迎今天早上加入電話會議的各位。我們以穩健的態勢展開 2024 年,在延續去年建立的動能之際,仍持續專注於營運卓越與以病患為中心的理念。我們再度交出一季成長,2024 年第一季在營收與調整後 EBITDA 方面,皆達成連續第四季年對年成長。Bausch Health(不含 B&L)營收為 10.5 億美元,按申報基礎增加 4,100 萬美元或 4%,按有機基礎增加 5%。與 2023 年第一季相比,所有事業部門在申報與有機基礎上皆實現營收成長,其中以 Solta 的 23% 有機成長領先。Bausch Health(不含 B&L)調整後 EBITDA 為 5.04 億美元,較去年同期約增加 9%。

  • We also continued to make progress on our key R&D initiatives during the quarter, in line with our established timing goals. First, for amiselimod in April, we met with the FDA for an end of Phase two meeting and a Phase three planning meeting for mild to severe ulcerative colitis UC. In addition, we were also pleased for amiselimod to have been accepted for a podium presentation at Digestive week on May 19th.

    本季我們也持續推進關鍵研發(R&D)計畫,並符合既定的時程目標。首先,關於 amiselimod,我們於 4 月與 FDA 召開第二期結束(end of Phase 2)會議,以及針對輕度至重度潰瘍性結腸炎(UC)的第三期規劃會議。此外,我們也很高興 amiselimod 已獲接受,將於 5 月 19 日的 Digestive Week 進行口頭(podium)發表。

  • Second, we completed enrollment for our second global Phase three trial for Red Sea in late April, which is slightly ahead of our goal of completion by the end of the first half of 2024. And third, we are pursuing approval of CAP TRIO for Canada and anticipate this could occur in the second half of the year.

    第二,我們於 4 月下旬完成 Red Sea 第二項全球第三期試驗的受試者招募,略早於我們原先設定在 2024 年上半年結束前完成的目標。第三,我們正推動 CAP TRIO 在加拿大的核准,並預期可能在今年下半年發生。

  • Overall, we continue to feel good about the progress we have made on our R&D pipeline and are progressing according to the timelines we shared in February.

    整體而言,我們對研發產品線的進展仍感到樂觀,並正依照我們在 2 月分享的時程推進。

  • Turning to our litigation with Norwich. On April 11th, 2024, the US Court of Appeals for the Federal Circuit affirmed the US District Court of Delaware's August 10th, 2022 judgment and also the May 17th, 2023 decision that had denied Norwich Pharmaceutical's motion for modification of the court's final order. We are pleased that the Federal Circuit maintain the judgment preventing the approval of Norwich as Anda for Xifaxan until October 2029.

    接著談我們與 Norwich 的訴訟。2024 年 4 月 11 日,美國聯邦巡迴上訴法院(US Court of Appeals for the Federal Circuit)維持美國德拉瓦州聯邦地方法院 2022 年 8 月 10 日的判決,以及 2023 年 5 月 17 日駁回 Norwich Pharmaceutical 變更法院最終命令之動議的裁定。我們很高興聯邦巡迴上訴法院維持該判決,使 Norwich 的 Xifaxan ANDA 在 2029 年 10 月之前不得獲准。

  • On April fifth, 2024, we filed a patent lawsuit against Amneal Pharmaceuticals following the receipt of a notice of Paragraph four certification stating that Amneal had submitted an NDA to the FDA seeking approval to market a generic version of Rifaximin this action formally initiate the litigation process under the Hatch Waxman Act and triggers a 30 month stay of any potential FDA approval for our meals and <unk> as a leader in gastroenterology health. We continue to vigorously defend our intellectual property and are committed to advocating for the safety of patients who have benefited from continued access to Xifaxan. We look forward to continuing to serve our patients and every patient deserves better health outcomes and the chance to make the most of life on the Granite trust matter. We continue to expect the settlement with the IRS to be finalized in the coming months. As we have previously indicated, the anticipated outcome of the settlement does not have material impact on the Company's results or cash flows. We continue to focus on our balance sheet and liquidity and ended the first quarter with approximately 1.5 billion of liquidity. In Q1, we repaid over 300 million of debt, including the 250 million of bonds with 2025 and 2026 maturities as noted on our year-end call.

    2024 年 4 月 5 日,在收到第四段(Paragraph IV)認證通知後,我們對 Amneal Pharmaceuticals 提起專利訴訟;該通知表示 Amneal 已向 FDA 提交 NDA,尋求核准上市利福昔明(Rifaximin)的學名藥版本。此舉正式啟動《Hatch-Waxman 法案》下的訴訟程序,並觸發對任何潛在 FDA 核准的 30 個月暫緩,並鞏固我們以及 <unk> 作為腸胃科健康領域領導者的地位。我們將持續積極捍衛智慧財產權,並致力於倡議曾因持續取得 Xifaxan 而受益之病患的用藥安全。我們期待持續服務病患;每位病患都應獲得更好的健康結果,以及把握人生的機會。關於 Granite trust 事項。我們仍預期與 IRS 的和解將於未來數月內完成定案。如我們先前所示,預期的和解結果不會對公司業績或現金流造成重大影響。我們持續專注於資產負債表與流動性,並於第一季末擁有約 15 億美元的流動性。第一季我們償還超過 3 億美元的債務,其中包括在年終電話會議中提及、到期日為 2025 年與 2026 年的 2.5 億美元債券。

  • Turning now to the potential full separation of Bausch & Lomb. Full separation of Bausch & Lomb continues to be a strategic priority. We continue to evaluate strategies regarding the potential full separation with the objective of ensuring that any transaction result into appropriately capitalized companies. The outcome at the quarter of appeals in the Norwich matter represents a significant milestone toward the full separation of B. and L. Any decision regarding if and when a separation occurs or its structure will be based on and subject to an assessment of all relevant factors and circumstances and a potential separation will also be subject to shareholder and other applicable approvals.

    接著談 Bausch & Lomb 可能的完全分拆。Bausch & Lomb 的完全分拆仍是策略優先事項。我們持續評估可能完全分拆的相關策略,目標是確保任何交易結果能使各公司具備適當的資本結構。Norwich 事項在上訴法院的結果,代表朝向 B. 與 L. 完全分拆的重要里程碑。任何關於是否以及何時進行分拆或其架構的決定,將以並受限於對所有相關因素與情況的評估;任何潛在分拆亦須取得股東及其他適用之核准。

  • Turning now to an overview of our segment performance for the quarter, starting on Slide 8. Salix revenue grew slightly year over year with reported growth of 1% and organic growth of 2%, driven by Xifaxan and RoE store, offset by net pricing pressure for true Lance and certain non-promoted products during the quarter we continued to see an increase in demand for our key products. Xifaxan relative store true ends with T. Rx growth of 3%, 3% and 9% respectively. Overall, Xifaxan revenues grew 8% over the first quarter of last year, reinforcing our strategy of continuing to make investments primarily in AI enabled sales tools, DTC. advertising, which we expect will drive further growth in this important franchise this year.

    接著概述本季各事業部門表現,從投影片第 8 頁開始。Salix 營收年對年小幅成長,申報成長 1%、有機成長 2%,主要由 Xifaxan 與 RoE store 帶動,但受到 true Lance 與部分未推廣產品於本季面臨淨定價壓力所抵銷;我們仍持續看到核心產品需求增加。Xifaxan relative store true ends 的 T. Rx 成長分別為 3%、3% 與 9%。整體而言,Xifaxan 營收較去年第一季成長 8%,強化我們持續投入的策略,主要聚焦於 AI 賦能的銷售工具與 DTC 廣告;我們預期這將在今年推動此一重要產品線進一步成長。

  • Turning to international, we saw solid year-over-year revenue growth during the first quarter with reported growth of 7% and organic growth of 2%. Organic growth was led by Canada, where we saw a strong performance from countries in the quarter. We have begun investing in DTC marketing for this product to build on this momentum. We were also pleased to receive our first public health plan listing for use areas, aerosol foam and Canada across the segment. We are also focused on driving long-term growth through investments in our promoted products and ongoing business development efforts.

    談到國際市場,我們在第一季看到穩健的年對年營收成長,按報告基礎成長7%,有機成長2%。有機成長主要由加拿大帶動,我們在本季看到該國表現強勁。我們已開始為此產品投資DTC(直接面向消費者)行銷,以延續這股動能。我們也很高興在本分部中,於加拿大就適應症範圍與氣霧泡沫劑型獲得首個公共衛生計畫納入給付名單。我們也專注於透過對重點推廣產品的投資與持續的業務開發工作,推動長期成長。

  • In Solta Medical revenues increased by 21% on a reported and 23% on organic basis, led by Asia Pacific. Importantly, we are pleased to see the US returned to growth, posting 14% year-over-year growth in revenue. We remain highly focused on maintaining momentum in Asia with Thermage FLX now approved as a medical device in China and on driving growth in the U.S. and EMEA markets where we believe there is meaningful opportunity in diversified, we delivered a solid quarter with 3% reported and 6% organic growth over the prior year. This was led by dermatology business. As we discussed on our year end call, CAP Trio launched in the US in late January and early script volume has been encouraging. We expect the new product to be a more significant contributor to the dermatology business over the remainder of the year. Neurology revenues grew slightly as we continue to capitalize on the opportunities in the market created by competitor supply constraints. While we did see volume declines in Wellbutrin and Aplenzin as expected improved net pricing led to higher sales of these products, reinforcing our strategy in managing script profitability. This growth was offset by continued pressures on our generics business and a slight decline in our dentistry business, where we expect our investments will lead to consistent growth through the remainder of 2024. Overall, we continue to focus on managing this mature portfolio of products for profitability and cash generation in a challenging competitive and pricing environment while looking for opportunities to make targeted investments where appropriate.

    Solta Medical營收按報告基礎成長21%,按有機基礎成長23%,主要由亞太地區帶動。重要的是,我們很高興看到美國市場恢復成長,營收年對年成長14%。我們仍高度專注於維持亞洲動能,Thermage FLX現已在中國獲核准為醫療器材;同時推動美國與EMEA市場的成長,我們相信在多元化方面存在顯著機會;我們本季表現穩健,按報告基礎成長3%,按有機基礎成長6%,較去年同期提升。這主要由皮膚科業務帶動。如同我們在年終電話會議中所討論,CAP Trio於1月底在美國上市,早期處方量令人鼓舞。我們預期該新產品在今年剩餘期間將成為皮膚科業務更重要的貢獻來源。神經科營收小幅成長,因我們持續把握競爭對手供應受限所創造的市場機會。雖然如預期我們在Wellbutrin與Aplenzin的銷量有所下滑,但淨價格改善帶動這些產品銷售額提高,強化了我們在管理處方獲利能力方面的策略。上述成長被學名藥業務持續承壓所抵銷,且牙科業務亦小幅下滑;我們預期相關投資將帶動2024年剩餘期間的持續成長。整體而言,在具挑戰性的競爭與定價環境下,我們仍專注於管理這個成熟產品組合,以提升獲利能力與現金創造,同時在適當之處尋找機會進行有針對性的投資。

  • Turning to the latest developments in our R&D pipeline.

    接下來談談我們研發(R&D)產品線的最新進展。

  • On Slide 9, starting with RGI. pipeline. As you will recall, in December, we announced positive top line results from our Phase two study evaluating Amisol Oman and as one P. antagonist for the treatment of UC. We held a Phase three planning meeting with the FDA in April and expect to meet with the international authorities, including in EMEA and Japan later this year.

    在第9頁投影片,先從RGI產品線開始。各位應該記得,我們在12月公布第二期研究的正向主要結果,該研究評估Amisol Oman與as one P. antagonist用於治療潰瘍性結腸炎(UC)。我們於4月與FDA召開第三期規劃會議,並預期今年稍晚將與包括EMEA與日本在內的國際主管機關會面。

  • In the meantime, we are pleased that amiselimod has been selected for a podium presentation on May 19th at Digestive Disease Week's annual conference, one of the largest and most prestigious events for gastroenterology professionals. We continue to move forward with planning for a Phase two program for Crohn's disease and expect to initiate that by the end of the year.

    同時,我們很高興amiselimod已獲選於5月19日在消化疾病週(Digestive Disease Week)年會進行口頭發表,該年會是胃腸科專業人士規模最大且最具聲望的活動之一。我們持續推進克隆氏症第二期計畫的規劃,並預期在年底前啟動。

  • Turning to our red T. program with rifaximin for reduction of early decompensation and cirrhosis, our global program focused on assessing the efficacy of our Rifaximin SSD formulation versus placebo to delay the occurrence of Empatic encephalopathy related hospitalizations. Both global Phase three trials for this program are underway. Enrollment for the first trial, as previously mentioned, completed in December 2023 and the enrollment for the second trial completed in April of 2024, which was ahead of our goal for the first half of 2024. Together, these studies are expected to include over 1,000 patients across North America, Europe and Asia Pacific.

    接著談我們以rifaximin進行的red T.計畫,用於降低早期失代償與肝硬化;此全球計畫聚焦評估我們的Rifaximin SSD配方相較安慰劑,在延後肝性腦病相關住院發生方面的療效。本計畫的兩項全球第三期試驗皆已進行中。如先前所提,第一項試驗已於2023年12月完成收案;第二項試驗則於2024年4月完成收案,早於我們原先設定的2024年上半年目標。合計而言,這些研究預計將納入超過1,000名病患,涵蓋北美、歐洲與亞太地區。

  • Turning now to our aesthetics pipeline, we are pleased to have their module FLX. and STR. four return path available to customers in China as of the second quarter, following the approval by the National Medical Products Administration in January 2024, we plan to file an FDA submission for our next-generation Fraxel in Q2, a fractionated laser device for skin resurfacing and anticipate approval could be received in the second half of this year.

    接著談我們的醫美產品線,我們很高興Thermage FLX與STR. four return path自第二季起可在中國提供給客戶;此前已於2024年1月獲國家藥品監督管理局核准。我們計畫在第二季向FDA遞交下一代Fraxel的申請,該產品為用於皮膚換膚的分段式雷射裝置,並預期可在今年下半年取得核准。

  • Finally, our program for Clear and Brilliant touch of fractionated laser device for skin rejuvenation continues to advance. We have received approvals in Australia and New Zealand this year, representing our first approvals outside of the United States and remain on track for regulatory submissions in 2024 in Europe, Canada and other Asia Pacific markets. We feel good about the progress we are making on these key R&D initiatives, and we remain focused on our pipeline of new market authorization and next-generation products as we continue to grow this global Sylvo portfolio of aesthetics products as a leadership team. We are committed to driving growth by leveraging our existing assets, making targeted investments and executing with commercial excellence while continuing to progress our pipeline, all with a patient centered mentality.

    最後,我們的Clear and Brilliant touch分段式雷射皮膚回春計畫持續推進。我們今年已在澳洲與紐西蘭取得核准,這是我們在美國以外的首次核准,並仍按計畫於2024年在歐洲、加拿大及其他亞太市場進行法規申請。我們對這些關鍵研發計畫的進展感到樂觀,並持續聚焦於新市場授權與下一代產品的產品線,作為領導團隊,我們將持續擴大全球Sylvo醫美產品組合。我們致力於透過運用既有資產、進行有針對性的投資並以卓越的商業執行來推動成長,同時持續推進產品線,一切以病患為中心的理念為依歸。

  • With that, I will turn the call over to John Bereznicki, who will provide further details on the first quarter performance.

    接下來,我將把電話會議交給John Bereznicki,他將就第一季表現提供更多細節。

  • John?

    John?

  • John Barresi - Interim Chief Financial Officer

    John Barresi - Interim Chief Financial Officer

  • Thanks, Tom, and hello, everyone, and thanks for joining us. We closed the first quarter with consolidated revenues for Bausch Health of 2.15 billion, up 11% on a reported basis and 8% on an organic basis over the same quarter last year. First quarter revenues for Bausch Health, excluding B&L, were 1.05 billion, up 4% on a reported basis and 5% on an organic basis over the same quarter last year with strong growth in Solta and low to mid single digit reported inorganic growth in our other segments.

    謝謝你,Tom,大家好,也謝謝各位加入我們。我們以第一季合併營收作結,Bausch Health合併營收為21.5億,按報告基礎年對年成長11%,按有機基礎成長8%,相較去年同期。Bausch Health第一季營收(不含B&L)為10.5億,按報告基礎年對年成長4%,按有機基礎成長5%,相較去年同期;其中Solta成長強勁,而其他分部則呈現低至中個位數的按報告基礎非有機成長。

  • Turning to segment revenue performance starting on slide 12, with Salix. First quarter sales revenues increased 3 million on a reported basis to 499 million, driven by TRx growth in our key products including Xifaxan five, 50 Relistor and true Lance revenues grew 12 million in an organic basis, reflecting the impact of divestitures and discontinuations of certain non-promoted products. Xifaxan continued to represent over 80% of Salix segment revenues this quarter and saw strong growth in underlying demand. Xifaxan revenues in Q1 increased 8% compared to the prior year period. Retail prescriptions grew 3% in Q1 versus the prior year. We saw another quarter of solid growth in TRx for IBS-D and the long-term care channel for HE extended units grew 4%, which included double digit growth in non-retail units attributable to outpatient clinics well as store delivered 10% growth over the prior year period with solid TRx growth of 3% and a benefit from favorable net pricing relative to Q1 of the prior year. Trulance revenues declined 7% year over year as solid TRx growth of 9% compared to Q1 of last year. Was offset by net pricing pressure. We also continued to experience meaningful net pricing pressure in our non-promoted portfolio in this segment.

    接著看第12頁投影片的分部營收表現,先從Salix開始。第一季銷售營收按報告基礎增加300萬至4.99億,主要由關鍵產品的TRx成長帶動,包括Xifaxan five、50 Relistor與true Lance;按有機基礎營收增加1,200萬,反映出售與停止銷售部分未推廣產品的影響。本季Xifaxan仍占Salix分部營收的80%以上,且基礎需求成長強勁。第一季Xifaxan營收較去年同期成長8%。第一季零售處方量較去年同期成長3%。我們在IBS-D的TRx再度出現穩健成長,而在長期照護通路方面,HE延伸單位成長4%,其中非零售單位出現雙位數成長,主要來自門診診所;同時,store delivered較去年同期成長10%,TRx穩健成長3%,且相較去年第一季受惠於有利的淨定價。Trulance營收年對年下滑7%,儘管TRx較去年第一季穩健成長9%。主要被淨定價壓力所抵銷。我們在本分部的未推廣產品組合也持續面臨顯著的淨定價壓力。

  • International revenues were 265 million during the quarter, an increase of 7% on a reported basis and 2% on an organic basis compared to the prior year period. Organic growth was led by Canada, while Lat-Am and EMEA were flat on an organic basis. Lat-am was impacted by the timing of government purchases with private channel sales. So in growth, while in Amea growth in key promoted products was offset by the effects of competition on certain of our non-promoted products. Total medical revenues were 88 million during the first quarter, an increase of 21% on a reported basis and 23% on an organic basis over the prior year period. Delta's growth was led by China and South Korea and to a lesser degree, the remainder of Asia Pacific. Importantly, the U.S. returned to growth this quarter with a 14% increase in revenues over the prior year. And we are continuing to invest in our sales force and related tools to drive sustainable growth in this key market.

    本季國際營收為2.65億美元,較去年同期按報告基礎成長7%,按有機基礎成長2%。有機成長主要由加拿大帶動,而拉丁美洲與EMEA按有機基礎持平。拉丁美洲受到政府採購時點與民間通路銷售時點影響。因此在EMEA方面,重點推廣產品的成長被競爭對我們部分非推廣產品的影響所抵銷。第一季醫療業務總營收為8,800萬美元,較去年同期按報告基礎成長21%,按有機基礎成長23%。Delta的成長主要由中國與南韓帶動,其次為亞太其他地區。重要的是,美國本季恢復成長,營收較去年同期增加14%。我們將持續投資於銷售團隊及相關工具,以在此關鍵市場推動可持續的成長。

  • Diversified revenues were 202 million during the first quarter, an increase of 3% on a reported basis and 6% on an organic basis compared to the prior year period. In dermatology, revenue grew by 16% on a reported basis and 25% on an organic basis in the quarter over the prior year period as we continued to focus on returning this business to consistent growth growth in the quarter, benefit from favorable net pricing comparisons quarter over quarter which we expect will moderate for the remainder of the year, while volumes for our non-promoted products continue to be pressured.

    第一季多元化業務營收為2.02億美元,較去年同期按報告基礎成長3%,按有機基礎成長6%。在皮膚科方面,本季營收較去年同期按報告基礎成長16%,按有機基礎成長25%;我們持續聚焦使該業務回到穩定成長。本季亦受惠於有利的淨定價比較(我們預期今年剩餘期間將趨於溫和),同時我們非推廣產品的銷量仍持續承壓。

  • As Tom noted, we are pleased with the early response in the market to cap Treos since its late January launch and expect it to become a more meaningful driver of growth in our dermatology business as the year progresses.

    如Tom所提,我們對cap Treos自1月下旬上市以來在市場上的早期反應感到滿意,並預期隨著年度推進,它將成為我們皮膚科業務更具意義的成長驅動因素。

  • Neurology revenues grew slightly posting a 1% increase year over year as we continued to benefit from competitor supply disruptions, although not at the same levels that we saw in Q4 of 2023, Wellbutrin and Aplenzin revenues grew despite lower volumes as we continue to execute our strategies to improve overall profitability in this business. While dentistry revenues declined modestly in the quarter compared to Q1 of last year. We continue to invest in this durable business for the long term and expect the investments we are making in the sales team and related tools to return this business to growth through the remainder of 2024.

    神經科營收小幅成長,年增1%;我們持續受惠於競品供應中斷,儘管程度不如2023年第四季。Wellbutrin與Aplenzin營收在銷量較低的情況下仍然成長,因我們持續執行提升該業務整體獲利能力的策略。同時,牙科營收在本季較去年第一季小幅下滑。我們將持續以長期角度投資這項具韌性的業務,並預期我們在銷售團隊及相關工具上的投資,將在2024年剩餘期間使該業務恢復成長。

  • As shown on slide 16, Bausch & Lomb revenues were 1.1 billion during the first quarter, up 18% on a reported basis and 11% on an organic basis compared to the prior year, with growth across all Bausch & Lomb segments, key product franchises and geographies.

    如投影片16所示,Bausch & Lomb第一季營收為11億美元,較去年同期按報告基礎成長18%,按有機基礎成長11%;成長來自Bausch & Lomb所有事業部門、主要產品系列與各地區。

  • Turning to the first quarter P&L on slides 18 and 20st quarter consolidated adjusted gross margin was 71.2%, 110 basis points higher compared with the prior year for Bausch Health, excluding B. and L. adjusted gross margin for the first quarter was 79.5%, approximately 20 basis points higher than last year's first quarter at B. and L. adjusted gross margin was 63.2% for Q1 of 24 compared to 60.0% for Q1 of 2023, driven primarily by product mix, including the impact of Zohydro.

    接著看投影片18與20的第一季損益表:合併調整後毛利率為71.2%,較去年提高110個基點。就Bausch Health而言(不含B. and L.),第一季調整後毛利率為79.5%,較去年第一季約提高20個基點;B. and L.第一季調整後毛利率為63.2%,相較2023年第一季的60.0%提升,主要由產品組合所帶動,包含Zohydro的影響。

  • Consolidated adjusted operating expenses for the first quarter were 916 million, an increase of 82 million for Bausch Health, excluding B&L adjusted operating expenses decreased by approximately 16 million compared to the first quarter of 2023. Higher A&P driven by investments in the dermatology and dentistry businesses and R & D were offset by lower G&A expenses. As we continue to focus on cost management, we expect A&P increases to moderate over the course of the year as we begin to annualize our investments in selling and marketing. For Salix, B&L reported an increase of $98 million in adjusted operating expenses due primarily to increased selling and A&P, driven by the addition of Zohydro and product launches, including Weibo.

    第一季合併調整後營業費用為9.16億美元,增加8,200萬美元。就Bausch Health而言(不含B&L),調整後營業費用較2023年第一季約減少1,600萬美元。因對皮膚科與牙科業務的投資而增加的A&P(廣告與促銷)以及研發費用,被較低的G&A(一般及行政)費用所抵銷。在我們持續聚焦成本管理之下,隨著我們開始將銷售與行銷投資年化,我們預期A&P的增幅將在今年逐步趨緩。就Salix與B&L而言,調整後營業費用增加9,800萬美元,主要因銷售與A&P增加,係由新增Zohydro及產品上市(包括Weibo)所驅動。

  • Consolidated adjusted R&D expense for the quarter was $150 million, an increase of 5% compared to the prior year and represented 7% of product sales compared with 7.4% for the prior year period. For Bausch Health, excluding B. and L. R & D expenses of $69 million increased by approximately 2 million for the first quarter as compared to the same quarter last year. This increase is in line with our expectations as we continued to invest in our GIN. aesthetics pipeline. First quarter consolidated adjusted EBITDA attributable to Bausch Health was $665 million, an increase of $77 million or 13% adjusted EBITDA for Bausch Health, excluding B&L, was $504 million for the quarter, a 9% increase from 462 million in the first quarter of 2023.

    本季合併調整後研發費用為1.50億美元,較去年增加5%,占產品銷售的7%,去年同期為7.4%。就Bausch Health而言(不含B. and L.),第一季研發費用為6,900萬美元,較去年同季約增加200萬美元。此增幅符合我們預期,因我們持續投資於GIN美學產品線的研發管線。第一季歸屬於Bausch Health的合併調整後EBITDA為6.65億美元,增加7,700萬美元或13%;Bausch Health(不含B&L)的調整後EBITDA為5.04億美元,較2023年第一季的4.62億美元成長9%。

  • Turning to cash flow, on a consolidated basis, Bausch Health generated 211 million of operating cash flow and 181 million of adjusted operating cash flow in the first quarter for Bausch Health, excluding B&L, adjusted operating cash flow was $133 million for the first quarter compared to adjusted operating cash flow of $94 million for the first quarter of 2023, with the changes primarily reflecting improved business performance, as we've discussed in prior quarters, as a result of the accounting treatment for the senior notes issued as part of our 2022 debt exchange. A portion of our cash interest payments are classified as financing cash flows adjusted cash flow includes payments of the full contractual interest as well as adjustments for the payment of separation costs, business transformation costs and litigation and other matters. Net of insurance proceeds Now let's turn to our balance sheet on Slide 19. We continue to prioritize liquidity management and the delevering of our balance sheet. In the first quarter, we reduced our debt from Bausch Health, excluding B&L, by 307 million, while debt net of cash decreased by $110 million, we continue to evaluate alternatives to reduce our overall leverage while also focusing on our maturity profile. As we discussed on the year-end earnings call, in January 2024, we retired 250 million in principal value of 2025 and 2026 maturities through open market repurchases, capturing approximately 12 million of discount in the process. We also repaid 56 million of additional debt consisting of mandatory term loan amortization and repaying a portion of our AR facility. At the end of the first quarter, Bausch Health, excluding B&L, had 325 million outstanding under our AR facility. It had no outstanding borrowings and approximately 950 million of availability under our revolving credit facility. As shown on slides 20 and 21, total debt for Bausch Health, excluding Bausch & Lomb at the end of the quarter was 16.1 billion, which consisted of approximately 14.8 billion of restricted debt issued by Bausch Health, excluding B&L, and approximately 1.3 billion of unrestricted debt, which includes the 1 billion of senior secured notes issued by the UnSub restricted subsidiary created in the third quarter of 2022 and of the $325 million drawn under our AR facility. Excluding D & L debt, approximately 85% of our debt is fixed and approximately 70% of the Company's debt on a consolidated basis is fix. We ended the quarter with approximately 1.5 billion of liquidity, which includes approximately 431 million of cash and 950 million of availability under our revolving credit facility. We are focused on strengthening our balance sheet, including evaluating and utilizing as appropriate various tools and strategies based on the provisions of our existing debt agreements, along with our existing liquidity to manage both our maturity profile and our overall leverage.

    接著看現金流:在合併基礎上,Bausch Health第一季產生2.11億美元的營運現金流與1.81億美元的調整後營運現金流。就Bausch Health而言(不含B&L),第一季調整後營運現金流為1.33億美元,較2023年第一季的9,400萬美元增加;變動主要反映營運表現改善,並且如我們在前幾季所討論,亦受到我們在2022年債務交換中發行之優先票據的會計處理影響。我們部分現金利息支付被分類為籌資現金流;調整後現金流包含依合約應付的全部利息,以及就分拆成本、業務轉型成本、訴訟及其他事項(扣除保險理賠收入)所作的調整。現在讓我們看投影片19的資產負債表。我們持續優先管理流動性並降低資產負債表槓桿。第一季,我們將Bausch Health(不含B&L)的債務減少3.07億美元;同時,扣除現金後的淨債務減少1.10億美元。我們持續評估降低整體槓桿的替代方案,同時也聚焦於到期結構。如我們在年終法說會所述,2024年1月,我們透過公開市場回購,償還了2025年與2026年到期債務本金價值2.50億美元,並在過程中取得約1,200萬美元的折價收益。我們亦額外償還5,600萬美元的債務,包括強制性定期貸款攤還,以及償還部分AR融資工具。第一季末,Bausch Health(不含B&L)在我們的AR融資工具下尚有3.25億美元未償餘額。在循環信貸額度下,未有任何未償借款,且可用額度約為9.50億美元。如投影片20與21所示,本季末Bausch Health(不含Bausch & Lomb)的總債務為161億美元,其中約148億美元為Bausch Health(不含B&L)所發行的受限制債務,另約13億美元為不受限制債務;不受限制債務包含2022年第三季設立之UnSub受限制子公司所發行的10億美元優先擔保票據,以及在我們AR融資工具下提用的3.25億美元。不含D & L債務,我們約85%的債務為固定利率;在合併基礎上,公司約70%的債務為固定利率。本季末我們的流動性約為15億美元,其中包含約4.31億美元現金及循環信貸額度下9.50億美元的可用額度。我們專注於強化資產負債表,包括依據現有債務協議條款,評估並在適當情況下運用各種工具與策略,並結合現有流動性,以同時管理到期結構與整體槓桿水準。

  • Turning to guidance, we are maintaining our guidance for the full year 2024 for Bausch Health, excluding B&L, we continue to expect revenue of 4.7 to $4.85 billion with organic growth of 2% to 5%, along with adjusted EBITDA of 2.36 billion to 2.46 billion and adjusted operating cash flow in a range of approximately 775 to $825 million.

    談到財測指引,我們維持對 Bausch Health(不含 B&L)2024 全年指引不變;我們仍預期營收為 47 億至 48.5 億美元,有機成長 2% 至 5%,同時調整後 EBITDA 為 23.6 億至 24.6 億美元,調整後營運現金流約為 7.75 億至 8.25 億美元的區間。

  • I'll now hand the call back to Tom.

    我現在把電話交回給 Tom。

  • Thomas Appio - Chief Executive Officer

    Thomas Appio - Chief Executive Officer

  • Thank you, John.

    謝謝你,John。

  • We continue to build on our strong global portfolio of businesses and remain highly focused on delivering against the objectives we laid out last quarter, including driving a result oriented culture of accountability, delivering on our revenue adjusted EBITDA and adjusted operating cash flow commitments, executing with operational excellence and cost focused mindset across the enterprise, intensifying our focus and operating rigor behind R&D and business development and continuing to evaluate strategic alternatives. Achieving the full separation of B&L remains a priority. These priorities help support our ambition of being a globally integrated health care company, trusted and valued by patients health care providers, employees and investors as we relentlessly drive to deliver better health outcomes.

    我們持續在強大的全球業務組合基礎上再接再厲,並高度專注於達成我們在上季提出的目標,包括推動以成果為導向、強調問責的文化;履行我們對營收、調整後 EBITDA 與調整後營運現金流的承諾;以卓越營運與成本導向的思維在全公司落實執行;加大對研發與業務開發的聚焦與營運紀律;並持續評估策略替代方案。完成 B&L 的全面分拆仍是優先事項。這些優先事項有助於支持我們成為全球整合型醫療保健公司的抱負,並讓病患、醫療照護提供者、員工與投資人信任與重視我們;同時我們將持續不懈地推動更佳的健康成果。

  • I would also once again like to extend my thanks to the entire Bausch Health team for their hard work. They have worked tirelessly and are all in to position our business for the long term. Every patient deserves better health and the chance to make the most of life. This drives us on with urgency and efficiency to deliver the products patients need most to enrich their lives on behalf of the entire Bausch Health team, I thank you for your interest and support of our company.

    我也想再次向整個 Bausch Health 團隊致謝,感謝他們的辛勤付出。他們不知疲倦地工作,全力以赴,為我們的業務長期發展奠定定位。每一位病患都應該擁有更好的健康,以及充分把握人生的機會。這驅使我們以更高的急迫感與效率,提供病患最需要的產品,豐富他們的生活。我代表整個 Bausch Health 團隊,感謝各位對本公司的關注與支持。

  • With that, we will now take questions. Operator, please open the line for Q&A.

    接下來我們將進入提問環節。接線員,請開放問答線路。

  • Operator

    Operator

  • (Operator Instructions) Glen Santangelo from Jefferies.

    (接線員指示) Jefferies 的 Glen Santangelo。

  • Glen Santangelo - Analyst

    Glen Santangelo - Analyst

  • Thanks for taking my question.

    謝謝讓我提問。

  • Hey, Tom.

    嗨,Tom。

  • Just a couple of quick ones for me. You reiterated a number of times, you know, that you remain committed to the full separation and you highlighted sort of the Norwich decision as being a significant milestone. What are the milestones or major milestones might exist? And then as you think about, you know, the strategies for a full separation, is it in your mind? Is the tax-free spin still the way to go are there or are there other strategies that you might be evaluating? And then maybe I just had a quick follow-up on the balance sheet.

    我這邊只有幾個簡短問題。你多次重申你們仍致力於全面分拆,並提到 Norwich 的裁決是重要里程碑。接下來還有哪些里程碑或主要里程碑可能存在?另外,當你們思考全面分拆的策略時,在你看來,免稅分拆(tax-free spin)仍是首選方式嗎?還是你們也在評估其他策略?最後我可能還有一個關於資產負債表的追問。

  • Thomas Appio - Chief Executive Officer

    Thomas Appio - Chief Executive Officer

  • Okay.

    好的。

  • Glenn, thanks for the question. Clearly, of course, the Norwich appeal decision is an important milestone. So we are really happy about that and really pleased with the outcome. But as you know, there's there's multi factors here that we need to consider. So as we as we take a look at it, you know, really the timing of the potential distribution, the most fundamental point is making sure that we have to appropriately capitalized companies so as we look at it, you know, as you know, there's moving parts when it comes to our balance sheet when it comes to other things in terms of litigation and what have you. So really kind of thoughtfully going through it and progressing through what what needs to be done?

    Glenn,謝謝你的問題。很明顯,Norwich 上訴裁決確實是一個重要里程碑。因此我們對此非常高興,也對結果非常滿意。但如你所知,這裡有多項因素需要我們考量。因此當我們檢視時,關於潛在分配的時點,最根本的一點是確保我們擁有資本配置適當的兩家公司;所以在我們評估時,如你所知,在資產負債表、訴訟等事項上都有一些變動因素。因此我們會審慎地逐項推進,完成需要做的事情。

  • What I would say is is when we look at it making sure. When when we take a look at the full separation, it is a priority for us as you as you can see, you know, on our priorities for 2024 it is a key priority to the full separation of B&L. And basically, as we've talked about before, you know, making sure again, we're totally in line with appropriately capitalized two companies and Tom, maybe just to follow up on that point on the balance sheet.

    我想說的是,當我們檢視時,必須確保——當我們看待全面分拆時,這是我們的優先事項;如你所見,在我們 2024 年的優先事項中,B&L 的全面分拆是關鍵優先事項。基本上,如同我們先前談過的,再次確保兩家公司都具備適當的資本結構;Tom,也許你可以就資產負債表這點再補充一下。

  • Glen Santangelo - Analyst

    Glen Santangelo - Analyst

  • When you think about the leverage on RemainCo, we've gotten a lot of pushback from investors. You know, highlighting the leverage related to, you know, the RemainCo post the spin, how you think about what the appropriate leverage ratio might be? I mean, you haven't sort of commented in a while on any of those leverage targets. But it seems you remain committed towards using various tools and strategies as you put it to kind of maybe work that debt level down so any sort of thoughts on how we should think about that through the balance of the year?

    當你思考 RemainCo 的槓桿時,我們從投資人那裡收到很多反對意見。也就是強調分拆後 RemainCo 的槓桿水準;你如何看待適當的槓桿比率可能是多少?我的意思是,你們有一段時間沒有就這些槓桿目標發表評論了。但看起來你們仍致力於使用各種工具與策略(如你所說)來逐步降低債務水位;因此,對於我們在今年剩餘時間應如何看待這件事,有沒有什麼想法?

  • Thomas Appio - Chief Executive Officer

    Thomas Appio - Chief Executive Officer

  • Yes. Look, Glenn, what I'll do is let me just take the first point is that and then I'll give it to John. But overall, as you saw this quarter and the last of four consecutive quarters, my focus one of my key focus is really driving growth driving performance. Of course, that always helps us be able to continue to retire debt. So we have a really healthy business globally. And as you saw the you know, the results for this quarter, both in the US and internationally, the business is growing and growing broadly. You saw the the and the performance of Solta. We really feel really great about the performance and the return to the performance in the U.S. of growth. So we have a really the business is healthy and doing well, a diverse portfolio of products and then clearly, we've exited we're back executing on our R&D pipeline and investing appropriately. So as we look at all those things, you know, we're positioning ourselves as we look at our balance sheet and what we can do. I'll hand it over to John to speak specifically on the balance sheet.

    是的。Glenn,我先回應第一點,然後交給 John。整體而言,如你本季所見,以及連續四季以來,我的重點之一就是推動成長、推動績效。當然,這也總是有助於我們持續償還債務。我們在全球擁有非常健康的業務。而如你看到本季的結果,無論在美國或國際市場,業務都在成長,而且是廣泛性的成長。你也看到 Solta 的表現。我們對其表現,以及在美國市場恢復成長的表現感到非常振奮。因此我們的業務非常健康、運作良好,產品組合多元;同時很明確地,我們已經走出過去的狀況,重新回到研發管線的執行,並進行適當投資。綜合上述,我們在檢視資產負債表以及可採取的作為時,正為自己做好定位。我把時間交給 John,請他就資產負債表做更具體的說明。

  • John Barresi - Interim Chief Financial Officer

    John Barresi - Interim Chief Financial Officer

  • Hey, Glenn, it's John. Thanks for the thanks for the question yet to the point of how do we think about a leverage target?

    嗨,Glenn,我是 John。謝謝你的問題。回到你提到的:我們如何看待槓桿目標?

  • I think it comes back to what Tom said a minute ago, right? Fundamentally, we're focused on to appropriately capitalized companies. And I think that's a there's no one binary point measure for that. It's really about balancing our leverage with our maturity profile. And as we've said, we're very focused on managing both of those effectively. We have a lot of tools at our disposal. As Tom said, we're focused on growing the business and it's a very cash generative business. You were guiding to seven 75 eight, $25 million of adjusted operating cash flow this year. We have a really broad diverse footprint, both product lines and geographically, and we think there's value in that. We're working on the pipeline, as you heard in Tom's prepared remarks earlier, and we'll use all of the tools that we have available, whether that's to do open market repurchases. We've done debt exchanges in the past. We've done asset sales in the past. We have the BLCO. stake of approximately 8% at our disposal and 1.5 billion of liquidity. So it doesn't directly answer your question of a point target, but those are all the things we think about as we think about managing the both the maturity profile and leverage.

    我認為這回到 Tom 剛才說的,對吧?從根本上,我們專注於打造資本配置適當的兩家公司。而我認為這不是一個單一、二元的指標點。更重要的是在槓桿與到期結構之間取得平衡。正如我們所說,我們非常專注於有效管理這兩者。我們手上有很多可用工具。如 Tom 所說,我們專注於推動業務成長,而這是一個現金創造能力很強的業務。你們看到我們今年調整後營運現金流的指引為 7.75 億至 8.25 億美元。我們在產品線與地理布局上都有非常廣泛且多元的版圖,我們認為這具有價值。我們也在推進研發管線,如你先前在 Tom 的事先準備發言中所聽到的;我們會運用所有可用工具,不論是進行公開市場回購。我們過去也做過債務交換。我們過去也做過資產出售。我們手上也有約 8% 的 BLCO 持股可供運用,以及 15 億美元的流動性。所以這並未直接以一個明確目標點回答你的問題,但以上就是我們在管理到期結構與槓桿時會考量的所有因素。

  • Glen Santangelo - Analyst

    Glen Santangelo - Analyst

  • Okay.

    好的。

  • Thanks for all the detail.

    感謝你提供這麼多細節。

  • Thank you.

    謝謝你。

  • Operator

    Operator

  • Your next question is coming from Michael Dell Kabbage from TD. Cohen. Your line is live.

    下一個問題來自 TD Cohen 的 Michael Dell Kabbage。您的線路已接通。

  • Michael Dell Kabbage - Analyst

    Michael Dell Kabbage - Analyst

  • Great.

    很好。

  • Thank you for the question.

    謝謝你的提問。

  • As has been noted, I think this is the first time at least in the recent past that management has explicitly connected the outlook for Xifaxan to the likelihood of completing the full separation of Bausch & Lomb. So that begs the question of when that segment outlook will be secure if we just consider the Amneal challenge and take the 30 month stay at face value, it would mean persistent uncertainty until almost 2027, which puts us right at the doorstep of four generic competition for Xifaxan. So I'm wondering how will it be possible to complete the Bausch & Lomb separation under those circumstances?

    如先前所提,我認為這至少是近期以來第一次,管理層明確把 Xifaxan 的展望與完成 Bausch & Lomb 全面分拆的可能性連結起來。因此就引出一個問題:如果我們只考慮 Amneal 的挑戰,並按 30 個月暫緩期的字面意思來看,那就意味著不確定性將持續到接近 2027 年,這正好來到 Xifaxan 面臨四家學名藥競爭的門口。所以我想請問,在這種情況下,要如何完成 Bausch & Lomb 的分拆?

  • Thomas Appio - Chief Executive Officer

    Thomas Appio - Chief Executive Officer

  • Yes, Michael, thanks for the question. It's I'm glad you asked it because I've seen a lot of things going back and forth in the press regarding and Neil. So So firstly, I just want to make sure we're clear is that it's a fax and is a is a huge product. Everybody looks at it. They're interested in it. The performance is great and it continues to perform and grow. You saw the quarter where we wound up with your highest TRXs on record all-time high. So it's doing well and it's growing and the investments we're making behind it. So paragraph fours, the Amneal issue was not unexpected. What I think the most important thing here is number one is that and the patents at issue here, you know, are not the same that were in the Norwich case. So there's new patents. So this is a you know, and we have a legal team. I am really in a great position to have such an outstanding legal team who is looking at it and working on it really, really hard. So they have no issue as we looked at it, what you have many patents there to consider as we work through. So I cannot speculate. You know, you know, again on what the strategy will be, but clearly Onyx, but it was not it wasn't that it was a surprise and we have a team that's working on it. So I don't really see that. And, you know, as we move forward as well, a situation that we're going to continue again, we'll probably see we could see others, but a time frame that it has, you know, we're going to work it real hard.

    是的,Michael,謝謝你的問題。我很高興你問到,因為我看到媒體上關於 Amneal 的各種說法來回傳。所以首先,我想先確認大家的認知一致:Xifaxan 是一個非常重要的產品。大家都在關注它。大家對它很有興趣。它的表現非常好,而且持續表現與成長。你也看到這一季我們的 TRx 創下歷史新高、史上最高。所以它表現良好、持續成長,我們也持續在背後投入。所以第四段,Amneal 這件事並不意外。我認為最重要的是第一點:這次涉及的專利,和 Norwich 案中的並不相同。所以是新的專利。因此這是……你知道的,我們有法務團隊。我很幸運能有這麼出色的法務團隊,他們正在非常、非常努力地研究並處理。所以他們在檢視後沒有疑慮;我們在推進過程中有許多專利需要一併考量。所以我無法臆測。你知道的,再次就策略會是什麼我不便推測,但很明顯……總之,這並不是意外,我們有團隊在處理。所以我不太認為這會……而且你知道,隨著我們往前推進,這種情況我們會持續面對;我們可能也會看到其他人,但就時間框架而言,我們會非常努力地處理。

  • Michael Dell Kabbage - Analyst

    Michael Dell Kabbage - Analyst

  • Let me ask a follow-up.

    我再追問一個問題。

  • Sure. Are you are you preparing for Norwich to file a new and just for the IBS indication, you suggested you may see others just now. And is there anything in your settlements with the other generics companies that would prevent them from doing the same thing?

    當然。你們是否在準備 Norwich 重新提出申請,而且只針對 IBS 適應症?你剛才也提到可能會看到其他人。另外,你們與其他學名藥公司的和解協議中,是否有任何條款能防止他們做同樣的事?

  • Thomas Appio - Chief Executive Officer

    Thomas Appio - Chief Executive Officer

  • Yes. So right now, as you know, we just got the ruling of the formation of the denial of the motion that Norwich is off the market until October of 2029. This is a a large milestone for us. I can't speculate what nor which will do you know, in the coming weeks or months, what I would say is, is we feel we have a great legal team because I was looking at it and monitoring it and we will see how it works out.

    是的。所以目前,如你所知,我們剛拿到裁定,確認駁回 Norwich 的動議,也就是 Norwich 在 2029 年 10 月之前不得上市。這對我們而言是一個重大的里程碑。我無法臆測 Norwich 在接下來幾週或幾個月會怎麼做;但我要說的是,我們覺得我們有一個很強的法務團隊,我也一直在關注與監控,我們會看看結果如何。

  • Michael Dell Kabbage - Analyst

    Michael Dell Kabbage - Analyst

  • Great.

    很好。

  • Thank you.

    謝謝。

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Your next question is coming from Douglas Miehm from RBC Capital Markets. Your line is live.

    下一個問題來自 RBC Capital Markets 的 Douglas Miehm。您的線路已接通。

  • Michael Dell Kabbage - Analyst

    Michael Dell Kabbage - Analyst

  • I think you first question just see in the past, the Company has discussed whether or not in its approach to and the distribution or the separation, you would comment on whether potentially could be a return of capital or butterfly. Is there anything that you can update us on as to the potential approach that the company may take in the event the you do pursue the separation?

    我想先問第一個問題:過去公司曾討論過,在分配或分拆的做法上,你們是否可能採取返還資本或 butterfly(蝶式交易)。如果你們確實推進分拆,對於公司可能採取的方式,有沒有任何最新進展可以更新?

  • Thomas Appio - Chief Executive Officer

    Thomas Appio - Chief Executive Officer

  • Yes, Doug, thanks for the question. Yes, we have talked about that in the past. At this point, no decision has been made. What I would say is we still are focused on making sure you know, it's deemed a tax-free to shareholders. So continuing to keep all options open and evaluating it as we progress.

    是的,Doug,謝謝你的問題。是的,我們過去確實談過。目前尚未做出任何決定。我想說的是,我們仍然專注於確保對股東而言被認定為免稅。因此我們會持續保留所有選項,並在推進過程中加以評估。

  • Michael Dell Kabbage - Analyst

    Michael Dell Kabbage - Analyst

  • Okay.

    好的。

  • And then second thing, just maybe you could give an update on the stock crop situation. I know you've been trying to resolve that, but we are getting close to a court data and belief on part of that.

    第二點,或許你可以更新一下 stock crop 的情況。我知道你們一直在嘗試解決,但我們也快接近法院日期了,我相信其中一部分是這樣。

  • And then finally, Wayne, I know this is really that not that important or material, but why is the IRS situation taking so long relative to when you thought you may be able to resolve that?

    最後,Wayne,我知道這其實不是那麼重要或重大,但為什麼 IRS 的事情相較於你們原先以為能解決的時間,拖了這麼久?

  • Thomas Appio - Chief Executive Officer

    Thomas Appio - Chief Executive Officer

  • Thank you.

    謝謝。

  • Is that the the IRSI. of course, are mostly is moving slow. I'll ask John to take that and then I'll come back to your question on the the opt-out.

    關於 IRS 的部分,當然,事情大多進展得很慢。我請 John 來回答,然後我再回到你關於 opt-out 的問題。

  • Hey, Doug, I think we'd love to have the settlement official and behind us as well. We're working that with with the IRS as expeditiously as we can. It's a really complicated matter as we've disclosed in the past, and we currently still expect that the settlement will not have a material impact on our results or on our cash flows. It's a process a matter of getting through the process?

    嗨,Doug,我想我們也很希望能讓和解正式定案並且告一段落。我們正盡可能迅速地與 IRS 推進。如我們過去揭露的,這是一個非常複雜的事項,而我們目前仍預期該和解不會對我們的業績或現金流造成重大影響。這就是一個把流程走完的問題。

  • I think at this point, yes.

    我想目前是的。

  • And then I'll just take the second. The first part of your question regarding the opt-outs. We've consistently no consistently knew that at some point we're going to have a trial date on, you know, the team has, again, as I pointed out earlier, the legal team has been working on this as you know, we settled the class we had. We've also settled 16 out of 37 opt out actions have either been settled or dismissed. The total remaining opt-out actions are pending or 21?

    接著我回答第二個——你第一部分關於 opt-out 的問題。我們一直都知道,在某個時間點會有一個審判日期;你知道的,團隊——如我先前指出——法務團隊一直在處理這件事;如你所知,我們已就集體訴訟達成和解。我們也已就 37 件 opt-out 訴訟中的 16 件達成和解或被駁回。剩餘仍在進行中的 opt-out 訴訟總數為 21 件?

  • What I would say is we know we have had, as you know, success on summary, judgment on some of the claims have been narrowed and we'll continue to work on it. And you know, we have what I would say is a strong litigation team, very focused on this, and we'll see how it progresses as we move Torino closer to a trial date.

    我想說的是,我們知道我們在部分主張上已在簡易判決方面取得成功,部分主張也已被限縮,我們會持續推進。而且你知道的,我們有一支我認為很強的訴訟團隊,非常專注於此;隨著我們逐步更接近審判日期,我們會看看進展如何。

  • Michael Dell Kabbage - Analyst

    Michael Dell Kabbage - Analyst

  • Okay.

    好的。

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Thank you. Your next question is coming from Huber Raffat from Evercore. Your line is live.

    謝謝。下一個問題來自 Evercore 的 Huber Raffat。您的線路已接通。

  • Michael Dell Kabbage - Analyst

    Michael Dell Kabbage - Analyst

  • Hey, guys. Thanks so much for taking my question. Maybe a couple of here, if I may. First, is there any regulatory body, US or ex-US or accreditor that needs a clarity on the effects? And within the 24 months post separation, is that an important gating factor for potential investors? That's point number one and number two for some of your debt liabilities coming up in 25 or so what are the plans? Are you intending to go down a very aggressive path? And then finally, do you envision any possible scenario where the spin has to be held off completely to take care of the amount of debt as well as FX situation.

    各位好。非常感謝讓我提問。如果可以的話,我想問兩個問題。第一,是否有任何監管機構(美國或非美國)或認證機構需要釐清這些影響?以及在分拆後的24個月內,這是否會成為潛在投資人的重要門檻因素?這是第一點;第二點是,針對你們在25年左右到期的一些債務負債,有什麼計畫?你們是否打算採取非常積極的路徑?最後,你們是否預見任何可能情境,因為需要處理債務規模以及外匯(FX)狀況,而必須完全延後這次分拆。

  • Thank you very much.

    非常感謝。

  • Thomas Appio - Chief Executive Officer

    Thomas Appio - Chief Executive Officer

  • Yes, former, thanks for the question. It's a question of right now. Let me just give the debt issue to John, maybe he can comment on that.

    是的,首先,謝謝你的問題。這是目前的一個問題。我先把債務的問題交給John,或許他可以評論一下。

  • Yes, Omar, I think we're certainly focused on our 25, all26 of our expertise really in our levers are 25 and 26.

    是的,Omar,我想我們當然聚焦在25年、以及26年;我們的專業與可運用的槓桿主要都在25年與26年。

  • I'll go back to what I said in one of the earlier questions, right? We have a number of tools at our disposal. We have 1.5 billion of liquidity. We have the ability to generate significant cash flow and a very cash-generative business. And we have the broad portfolio that we have with a number of valuable assets, including the the stake of BBLCO. that we can distribute while staying above that tax-free distribution threshold. And so we're looking at all of those as ways to manage and manage our maturities. Beyond that, I will I won't comment on any specific things that we may do. Other than to say, we've done a combination of all of these things in the past, our MRs, debt exchanges, asset sales, and we'll continue to look at all of those levers.

    我回到我在前面某個問題中說過的,對吧?我們手上有多種工具可用。我們有15億美元的流動性。我們有能力產生可觀的現金流,而且我們的業務非常能產生現金。此外,我們擁有廣泛的投資組合,包含多項有價值的資產,包括BBLCO的持股;在維持高於免稅分配門檻的情況下,我們也可以進行分配。因此,我們正把上述各項都視為管理到期債務的方式。除此之外,我不會評論我們可能會做的任何具體事項。只想說,我們過去曾把這些方式做過各種組合,包括MRs、債務交換、資產出售,我們也會持續評估所有這些槓桿。

  • John Barresi - Interim Chief Financial Officer

    John Barresi - Interim Chief Financial Officer

  • Yes, Rob, I'll take the first point of your question. I'm not aware of any specific Xifaxan regulatory body, you know, in the U.S. or ex U.S. What I would say is that I've said many times, he's really making sure we have to appropriately capitalized companies.

    是的,Rob,我來回答你問題的第一點。我不知道有任何特定的Xifaxan監管機構,不論在美國或美國以外。我想說的是,我已經多次提到,我們真正要做的是確保公司有適當的資本化。

  • And to the last part of your question is, you know, our priority is the full separation of B&L. So and as we work through it as I said earlier, it or you have some on my prepared remarks and into earlier questions is really there's a progression as we work it through, and we'll keep everyone updated as we work work it.

    至於你問題的最後一部分,你知道,我們的優先事項是讓B&L完成全面分拆。因此,當我們推進這件事時,正如我先前所說、也在我準備好的發言以及前面問題中提到的,整體會有一個逐步推進的過程;我們會在推進的同時持續向大家更新。

  • But I really appreciate the question.

    但我非常感謝你的提問。

  • Michael Dell Kabbage - Analyst

    Michael Dell Kabbage - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Thank you. Your next question is coming from Chi Fong from Bank of America. Your line is live.

    謝謝。下一個問題來自美國銀行(Bank of America)的Chi Fong。你的線路已開通。

  • Hey, good morning.

    嗨,早安。

  • This is Chi on for Jason Gerberry at CFAI. Thanks for taking our questions. And I guess on the first one, now that you've secured the Norwich ruling, has the Company been in discussion with claimants in the fraudulent conveyance matter about a potential settlement and a couple of follow-ups after this?

    我是Chi,代Jason Gerberry(CFAI)提問。謝謝讓我們提問。第一個問題是,既然你們已取得Norwich裁定,公司是否已就詐欺性移轉(fraudulent conveyance)案件與索賠方討論過潛在和解?後面我還有幾個追問。

  • Yes, cheap basis, I can't comment you know know what have we been in discussions, you know, can't really and discuss that at this time. But again, we're always open to discussions and looking at the options you had a follow-up question.

    是的,基於成本考量,我無法評論我們是否正在進行討論;目前也不便談這件事。但同樣地,我們一向願意進行討論並評估各種選項。你有追問嗎?

  • Yes. A couple of follow-up. One on the first one is on SG&A. So we look at 1Q, the spend ratio looks a lot of high in the mid 30s. I'm wondering if there's any 1Q seasonality truck drive the ratio higher than usual? Or if not, how do you see that SG&A spend ratio evolving in the coming years at GRE.

    有。幾個追問。第一個是關於SG&A。我們看1Q,費用率看起來偏高,在30%中段。我想知道1Q是否有任何季節性因素推升費用率、使其高於平常?如果沒有,你們如何看待未來幾年在GRE的SG&A費用率走勢?

  • Looking consolidated?

    你是看合併口徑嗎?

  • Yes, consolidated.

    是的,合併口徑。

  • Yes.

    好的。

  • So I think on BALCO spoke a little bit to this yesterday as well. There has been a significant A&P investment on the BLCO. side supporting both Cidra and some of their product launches like Maipo. And that is that is on a consolidated basis.

    我想在BALCO方面,昨天也稍微談到這點。BLCO端有相當顯著的A&P(廣告與促銷)投資,用來支持Cidra以及一些產品上市,例如Maipo。而這些在合併口徑下都有反映。

  • I think the biggest driver there.

    我認為這是最大的驅動因素。

  • Okay, got it. And my last one is on the pipelines on MSL. What were there any surprising points of feedback from the end of Phase two? And as you come off this FDA meeting, I understood that you still have discussions with international agencies, but do you have any early thoughts on your Phase three strategy as you look to capture the entire spectrum of mild-to-moderate UC and then I think you have mentioned that you are still considering a Phase two trial in Crohn's. I'm curious, did the recent Phase two trial of Phase three failure from ozanimod in Crohn's. Also, you're thinking about continued investment in Crohn's there.

    好的,了解。最後一個問題是關於MSL的產品線(pipeline)。第二期試驗結束後,有沒有任何出乎意料的回饋重點?另外,在這次FDA會議之後,我理解你們仍在與國際機構討論,但就你們希望涵蓋輕度到中度UC的完整族群而言,對第三期策略是否已有初步想法?另外我記得你們提到仍在考慮在克隆氏症(Crohn's)做第二期試驗。我想了解,近期ozanimod在克隆氏症的第二期試驗/第三期失敗,是否也影響你們對於持續投資克隆氏症的想法。

  • We achieved that.

    我們做到了。

  • Thank you for the question on the business and the pipeline, I really appreciate that. You know that as you know, a really focused on the pipeline, a Red Sea as we had fully enrolled these two trials really are really interested in getting them completed. When we look at Amisol i-mode. We are really happy that we were accepted on the podium at DDW, which is coming up later this month. And presenting that to, you know, our data as you know in our press release, we were really pleased with the with the data that we had on our Phase two very large Phase two trial of our strategy here is you know the meeting with the FDA, it went well and where we're progressing on this. We know from a UC perspective, when we look at it, we see this market very large and we think we have a product that can compete here very nicely. So, you know, really well, by the time we're ready to launch. We're probably looking at between your market in oh seven to $8 billion. So really a great growth driver for us in the back half of the decade. I'm looking at the Phase three trial hoping to get that up and running later this year or the beginning of 2025.

    謝謝你關於業務與產品線的問題,我非常感謝。如你所知,我們非常聚焦在產品線;在我們已完成這兩項試驗的全數收案後,我們也非常希望把它們完成。當我們看Amisol i-mode時,我們很高興能在本月稍晚舉行的DDW上獲選上台發表。並向大家呈現我們的數據;如你所知,在新聞稿中,我們對第二期(規模很大的第二期)試驗數據感到非常滿意。就我們的策略而言,與FDA的會議進展順利,我們也正在推進。從UC的角度來看,我們認為這個市場非常大,而且我們認為我們有一個產品能在此市場中很好地競爭。因此,你知道,等到我們準備上市時,我們可能看到市場規模約在70億到80億美元之間。所以這會是我們在本十年後半段很重要的成長驅動力。至於第三期試驗,我們希望在今年稍晚或2025年初啟動並開始運作。

  • And on Crohn's, again, as you know, this is a real large market. We would really love to be participating here. We think we have, you know, based on our data what we've seen, you know, out of the UC trial that we were going to run a Phase two plan a Phase two model with moderate to severe and CD. and E., again, nine over $19 billion market. And we think we have a drug that can compete now of course, yes, you mentioned that the failures of S. one piece in Crohn's. But when we look at this trials in Phase two and how we're going to structure it, we think we can have some success.

    至於克隆氏症,同樣地,如你所知,這是一個非常大的市場。我們非常希望能參與其中。我們認為,基於我們看到的數據、以及從UC試驗得到的結果,我們將在中重度CD(克隆氏症)上規劃一個第二期方案;同樣地,這是超過190億美元的市場。我們認為我們有一款藥物可以競爭;當然,是的,你提到S. one piece在克隆氏症上的失敗。但當我們看第二期試驗以及我們將如何設計時,我們認為仍有機會取得一些成功。

  • Thank you for the question, though. Really appreciate the question, pipeline.

    不過還是謝謝你的提問。非常感謝這個問題,關於產品線。

  • Thank you.

    謝謝。

  • Your next question is coming from David Amsellem from Piper Sandler. Your line is live and headache.

    下一個問題來自 Piper Sandler 的 David Amsellem。您的線路已接通。

  • So just a couple of questions, a long-term focus question. In terms of your Rifaximin business, how are you thinking about erosion of the franchise once you do see generic competition materialize. And I guess what I'm trying to get at is what are your expectations surrounding the next-generation Rifaximin products as a means of cushioning some of the impact of generic competition. So that's number one.

    我有幾個問題,偏長期焦點。就你們的 Rifaximin 業務而言,一旦看到學名藥競爭出現,你們如何看待該產品線(franchise)的侵蝕。我想問的是,你們對下一代 Rifaximin 產品的期待是什麼?它是否能在一定程度上緩衝學名藥競爭帶來的影響。這是第一個問題。

  • And then number two, and I know you alluded to it on the prior question, but on emicizumab, did you have a sense based on your own market research, how you're thinking about the sales potential here in the context of an increasingly crowded market with other agents that have novel mechanisms such as the TO. one a. is how do you think about on a sales potential for Fermacell amounts to the extent that you commercialize it?

    第二個問題,我知道你們在上一題有提到一些,但就 emicizumab 而言,根據你們自己的市場研究,在一個愈來愈擁擠、且有其他具新穎機轉(例如 TO)的藥物競爭的市場環境下,你們如何看待這裡的銷售潛力?也就是說,若你們將其商業化,你們如何評估 Fermacell 的銷售潛力?

  • Thanks it, David. So no, firstly, again, thanks for the question on the pipeline. I'm really glad this kind of questions are on the pipeline in the business today. Red Sea. I just as I look at this program, when I took over as CEO. One of the things I worked with our head of R&D is to really accelerate this trial. Clearly, you mentioned zone with is eFax and going off patent. How do we fill that gap. And when we look at where we're going to get to a timing of launch for Red Sea, we're progressing it and we're really trying to execute with excellence to get there, you know, prior to the effects and going off patent, you know, yes. And also I'd like to point out here we have this is a global program. We have global rights. This is a new formulation. So this really opens us up, as you know, Salix, a long history in the US in gastroenterology and liver. Now this really gives us a platform globally with Red, say, if we just kind of put some numbers around that, just when we look at the just in the U.S. alone, again, this is a prevention. This is going towards prevention. So the pool is much larger homes that we can we can look to in the US. So if you just say, you know, the cirrhotic patients in the US today were around 800, 800,000. And then if you take out the patients that have HE today, given that it's prevention now you're at about six 56, 56 hundred K. And if you look at the facts and today you have 100 and so you have over 150,000 in ag, we're treating only 25% of that. So you look at the pool that we have to have patients on a prevention and then that's just in the U.S. If you then model that out to the US to international markets and building a GI. liver portfolio in the international space, as we talked about our international business is we've got we have really great platforms around the world, and I see a great opportunity here. You know, as we of course, you need the data, but it's a it's really exciting what we're on the Red Sea when we take a look at it.

    謝謝你,David。首先,再次謝謝你對產品線的提問。我很高興今天的業務討論中會有這類關於產品線的問題。Red Sea。我在接任 CEO 時回頭看這個專案。我和我們的研發主管合作的一件事,就是要真正加速這項試驗。很明顯,你提到 Xifaxan 將到期失去專利保護。我們要如何填補這個缺口。當我們看 Red Sea 的上市時程時,我們正在推進它,並且努力以卓越的執行力在 Xifaxan 失去專利之前達成,你知道,是的。另外我也想在此指出,這是一個全球性計畫。我們擁有全球權利。這是一個新的劑型。因此這確實為我們打開了機會;如你所知,Salix 在美國的腸胃科與肝病領域有很長的歷史。現在,Red Sea 讓我們在全球有了一個平台;如果我們用一些數字來說明,僅看美國市場,這同樣是一個預防性治療。這是朝向預防。因此在美國我們可以著眼的族群規模要大得多。如果你只看美國目前的肝硬化患者,大約是 80 萬人。再把目前已有 HE 的患者扣除,因為現在是預防,你就會剩下大約 56 萬人。而如果你看 Xifaxan 目前的情況,你有超過 15 萬名患者在使用,但我們只治療了其中約 25%。所以你看我們可用於預防治療的患者池,這還只是美國;如果再把模型延伸到美國以外的國際市場,並在國際市場建立 GI/肝病產品組合——正如我們談到的,我們的國際業務在全球各地都有很好的平台——我在這裡看到很大的機會。當然,你需要數據,但就我們對 Red Sea 的評估而言,這真的令人振奮。

  • Your second question is, as I talked about Amisol mode, I'm really excited about it as well. You know, looking forward to getting into our Phase three a Phase three program. And again, yes, the the R&D team, a real focus because we know we had we're losing defects. And so where can we close these gaps? One of them is with Red Sea, another can be with Amatil i-mode. What I would say also is, you know, our BD team, I think one of the things that we have done over the last two years, we have built a really strong BD team. And so therefore, we are looking to be able to find some assets that we can bring in to slot into our businesses in the United States and in international that can close the gap as well.

    你的第二個問題,正如我談到 Amisol mode,我也非常興奮。你知道,我們期待進入第三期、第三期計畫。同樣地,是的,研發團隊非常聚焦,因為我們知道我們將失去 Xifaxan。那麼我們可以在哪裡補上這些缺口?其中之一是 Red Sea,另一個可能是 Amatil i-mode。我還想說的是,你知道,我們的 BD 團隊——我認為過去兩年我們做的一件事,是建立了一支非常強的 BD 團隊。因此,我們也在尋找能夠引進、並可嵌入我們美國與國際業務的資產,以同樣方式補上缺口。

  • So this is a real priority for us.

    所以這對我們來說是一個真正的優先事項。

  • That's why you see it, you know, in our priorities of how to really accelerate the pipeline. But also from a BD perspective, we have screened a number of assets and we have to be we have to be really on pedantic about it to make sure that we bring in the right asset and making sure from what does it fit what does the cost and also remember, you know, one of our you know, our pillars is making sure that that quality product we in the the quality of the products as we do diligence, we're making sure that the products that we can bring into this company are high quality and continue to build a a great pharmaceutical company. But thank you for the question. Really appreciate it.

    這也是為什麼你會看到,在我們的優先事項中,包含如何真正加速產品線。但同時從 BD 的角度,我們已篩選了多個資產,而我們必須非常嚴謹地看待,確保引進的是正確的資產,並確認它是否契合、成本如何;同時也請記得,我們的支柱之一是確保品質——在盡職調查時,我們會確保能帶進公司的產品具高品質,並持續打造一家優秀的製藥公司。但謝謝你的提問。非常感謝。

  • Thank you.

    謝謝。

  • Your next question is coming from Liz Suzuki from Truist Securities. Your line is live.

    下一個問題來自 Truist Securities 的 Liz Suzuki。您的線路已接通。

  • Good morning. Thank you for taking my questions. Actually do have a couple of follow up on the pipeline. So on your Reg G program with enrollment in both trials now a complete, can you handicap a time line for top line results in low. Would you disclose data from one study or both together? And is there a possibility we released preliminary data on?

    早安。謝謝讓我提問。我其實有幾個關於產品線的追問。關於你們的 Reg G 計畫,兩項試驗目前都已完成收案,你能否提供主要結果(top line results)的時間表?你們會揭露單一研究的數據,還是兩項一起公布?是否有可能先發布初步數據?

  • And then secondarily, on cap Trio, if there are any initial feedback from prescribers on regarding the trends that you're seeing and how sizable ultimately this market within the category and also your plans for launching into Canada once approved and then third on Thermage, what does the market strategy to or go-to-market strategy in China? And how big is the opportunity there for you in that product launch?

    第二,關於 cap Trio,處方醫師是否有任何初步回饋,針對你們看到的趨勢?以及最終在該類別中,這個市場規模有多大?另外,一旦獲批,你們在加拿大上市的計畫是什麼?第三,關於 Thermage,在中國的市場策略或上市策略(go-to-market strategy)是什麼?在該產品上市方面,對你們而言機會有多大?

  • Thank you, Les.

    謝謝你,Liz。

  • Thanks, for the question. So on underwritten, I'll take the first one on Red C. Again, trying to make sure that we have read see, you know, prior to the loss of Xifaxan would be keep right now, hoping we get and data, you know, in late 2025, early six, and we'll see again making sure that that trial is on track and can deliver. And then, of course, you know, being able to file it and get it registered not only in the U.S. but around the world. So that's where I see the timeframe really comes down to making sure that again, going back to the previous question on filling our gap and knowing Xifaxan is going where it is going to be going generic in 2028 cap Trio. We're excited about it. You know, they love the product. The R & D team has done a wonderful job here. We think have a great product for acne. The team is really all in and focused on driving this. If I just look at the script growth, it's ahead of our goal that we have set again a very crowded space. But really this is a great product and the feedback from our customers and patients has been really strong.

    謝謝你的問題。關於你提到的第一個 Red C。同樣地,我們希望確保 Red Sea 能在 Xifaxan 流失之前推出;目前我們希望在 2025 年底、2026 年初取得數據,我們也會持續確保試驗按計畫進行並能交付結果。接著,當然,我們要能夠提交申請並取得核准,不僅在美國,也包括全球各地。所以我看到的時間框架,最終還是回到:確保我們能填補缺口,並且知道 Xifaxan 將在 2028 年面臨學名藥化。cap Trio 方面,我們對它感到很興奮。你知道,大家很喜歡這個產品。研發團隊在這裡做得非常出色。我們認為這是一個很好的痤瘡產品。團隊全力投入並專注於推動它。如果我只看處方量(script)成長,它高於我們設定的目標——同樣地,這是一個非常擁擠的市場。但這確實是一個很棒的產品,且我們從客戶與患者那裡得到的回饋一直非常正面。

  • What I would say also is, is, you know, it's in early stages, we launched it and then we actually launched it ahead of having samples. So we're I'm really excited now that we have we have the samples coming on we also have the DTC campaign that will happen, you know, coming up in the next few months. So this is really a focus for our derm business and the R&D team has done an outstanding job here of bringing a great product to the market for patients at the March FLX in China. Again, I am real excited. As you know, I lived in China for many years. So you know, this market extremely well. I think we have an outstanding opportunity. As you saw the performance of our business this quarter has been was outstanding led by China, led by in Asia Pacific as well. We are looking at our strategies on their mode. I would say we just had the launch meeting last week and it went extremely well. And our strategy here is is again, if you if you look at the opportunities in China today and we and you hear a lot about the economics of China. You know, in terms of post COVID, you hear a lot about the property market. But if you look at the patients that we target an EV and you look at that, even though in China, the COVID had an impact, but there was also a lot of savings that took place. So the so there weren't traveling were doing many things so there we see that our patient population has and the opportunity and the economics to use our products. And what you see also in China, you see that that noninvasive treatments are very, very popular. Solta has a great name in China. We have a great brand. So now having it approved by the NMPA as the first RF device to be approved we think we have a great opportunity. We're building our team. In fact, I'm going to be in China in the next couple of weeks to talk to the team, make sure we have the strategies in place and then executing those strategies accordingly. But I lived there for many years. So I'm really confident we are going to have a real successful business in China. We're and we I'm piggybacking on it, we already do, but we're just going to grow more on that.

    我還想補充的是,你知道,這還在早期階段,我們已經推出了,而且其實是在還沒有樣品之前就先行上市了。所以我現在真的很興奮,因為我們已經有樣品陸續到位,同時我們也會啟動DTC(直面消費者)行銷活動,你知道,會在接下來幾個月內展開。因此,這確實是我們皮膚科業務的重點,而研發團隊在這方面表現非常出色,為患者把一款很棒的產品帶到市場上,並在中國於3月推出FLX。再次強調,我真的非常興奮。如你所知,我在中國生活了很多年。所以你知道,我對這個市場非常了解。我認為我們有非常出色的機會。正如你所看到的,我們本季業務表現非常亮眼,主要由中國帶動,也由亞太地區帶動。我們正在檢視我們在那裡的策略模式。我想說的是,我們上週剛開完上市會議,進展非常順利。而我們在這裡的策略是——再次強調——如果你看看當今中國的機會,以及你也常聽到很多關於中國經濟的討論。你知道,就後疫情時代而言,你會聽到很多關於房地產市場的話題。但如果你看看我們鎖定的患者族群,以及你再看,即便在中國,COVID確實造成影響,但同時也出現了大量的儲蓄累積。所以,因為大家不旅行、不做很多事情,因此我們看到我們的患者族群具備使用我們產品的機會與經濟能力。而你在中國也會看到,非侵入式療程非常、非常受歡迎。Solta在中國有很好的口碑。我們有很強的品牌。所以現在作為首款獲NMPA核准的RF設備,我們認為我們有很好的機會。我們正在擴建團隊。事實上,我接下來幾週會去中國與團隊交流,確保我們的策略到位,並據此落實執行。但我在那裡住了很多年。所以我非常有信心,我們將在中國打造一個非常成功的業務。而且——我也順帶一提——我們其實已經在做了,只是我們會在此基礎上進一步成長。

  • Thank you for the question.

    謝謝你的提問。

  • Thank you. We've reached the end of the question and answer session. I'll now hand the conference back to Chief Executive Officer, Thomas appeal for closing remarks.

    謝謝。我們已經到達問答環節的尾聲。接下來我將把會議交回給執行長Thomas appeal,請他做結語。

  • Please go ahead.

    請開始。

  • Yes.

    是。

  • What I would just tried to say to everyone on the call. I really appreciate everyone's questions today, you know, and really making sure that we're looking at the performance of our business and what the pipeline is. And what the future can be. So I really thank everyone for joining today. As I said many times, we had a solid Q2, fourth consecutive quarter of growth. I really want to build on this momentum in Q2. I would also say is the team here at Bausch Health is all and we know what we need to do and really making sure we execute with excellence. So you know, making sure you saw the priorities, what our priorities are delivering our commitments and continuing to position this Company for the future. And what I lastly, I'd like to say is look forward to keeping you all updated and really thank you for your interest in and support of our company. Really appreciate it and have a great day, everyone.

    我只是想對所有在線上的各位說。我非常感謝大家今天的提問,你知道,並且確保我們在檢視我們業務的表現以及產品管線是什麼。以及未來可能會是什麼樣子。所以我非常感謝大家今天的參與。正如我多次提到的,我們第二季表現穩健,連續第四個季度成長。我真的希望在第二季的基礎上延續這股動能。我也想說的是,Bausch Health的團隊非常投入,而且我們知道我們需要做什麼,並確保我們以卓越的方式執行。所以你知道,確保你們看到了我們的重點,我們的優先事項是兌現我們的承諾,並持續為公司的未來做好定位。最後我想說的是,我期待持續向各位更新進展,也非常感謝你們對我們公司的關注與支持。真的非常感謝,祝大家有美好的一天。

  • This concludes today's event. You may disconnect at this time, and have a wonderful day. Thank you for your participation.

    今天的活動到此結束。您現在可以斷線,祝您有美好的一天。感謝您的參與。